Navigation Links
Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
Date:9/3/2009

SUNNYVALE, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that Dr. Glenn Rice, President and COO, will provide a business overview at the following conferences:

-- Thomas Weisel Partners 2009 Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 9th at 3:50 p.m. EDT.

-- Rodman & Renshaw 11th Annual Healthcare Conference at the Palace Hotel in New York on Thursday, September 10th at 12:05 p.m. EDT.

There will be a live webcast of the presentations, which will be accessible through a link posted on the investor relations / events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm. The webcasts will be available for replay through October 10th, 2009.

About Pharmacyclics

Pharmacyclics((R)) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us athttp://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmacyclics, Inc. Rights Offering Oversubscribed
2. Pharmacyclics Announces Subscription Price for Rights Offering
3. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
4. Pharmacyclics Files Registration Statement for Rights Offering
5. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
6. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
7. Pharmacyclics Secures $5.0 Million in Debt Financing
8. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
9. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
10. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
11. Pharmacyclics Announces It Received Nasdaq Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):